{
    "clinical_study": {
        "@rank": "73958", 
        "arm_group": [
            {
                "arm_group_label": "Sofosbuvir+RBV 12 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants with genotype 1, 2, or 6 will receive sofosbuvir+RBV for 12 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+RBV 16 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 16 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+RBV 24 Weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of sofosbuvir+ribavirin (RBV) in\n      treatment-naive adults with chronic genotype 1, 2, 3 or 6 HCV infection, and in\n      treatment-experienced adults with chronic genotype 2 HCV infection.\n\n      The study will be conducted in China, Hong Kong (HK), Korea, Taiwan, and Vietnam.\n      Participants will be enrolled in the study for 12, 16, or 24 weeks of treatment."
        }, 
        "brief_title": "Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HCV Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide written informed consent\n\n          -  HCV RNA \u2265 10^4 IU/mL at screening\n\n          -  HCV treatment-naive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any\n             interferon (IFN), RBV, or other approved or experimental HCV-specific direct-acting\n             antiviral agent, or HCV treatment-experienced (HCV genotype 2 only) with medical\n             records that include sufficient detail of prior treatment with IFN to allow for\n             categorization of prior response as either IFN Intolerant, non-responder, or\n             experiences viral breakthrough or relapse\n\n          -  HCV infection documented by ant-HCV antibody test, genotyping test, or liver biopsy\n\n        Exclusion Criteria:\n\n          -  Current or prior history of any clinically-significant illness (other than HCV)\n\n          -  Pregnant or nursing female or male with pregnant female partner\n\n          -  Chronic liver disease of a non-HCV etiology\n\n          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "486", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02021643", 
            "org_study_id": "GS-US-334-0115"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 12 weeks", 
                    "Sofosbuvir+RBV 16 weeks", 
                    "Sofosbuvir+RBV 24 Weeks"
                ], 
                "description": "Sofosbuvir 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-7977", 
                    "PSI-7977", 
                    "Sovaldi\u00ae"
                ]
            }, 
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 12 weeks", 
                    "Sofosbuvir+RBV 16 weeks", 
                    "Sofosbuvir+RBV 24 Weeks"
                ], 
                "description": "Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug", 
                "other_name": "Ribasphere\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ansan-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "425-707"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucheon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "420-767"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "405-760"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seongnam-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "467-707"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-715"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "614-735"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "700-721"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "152-703"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-720"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "735-710"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changhua City", 
                        "country": "Taiwan", 
                        "zip": "50006"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung City", 
                        "country": "Taiwan", 
                        "zip": "82445"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung City", 
                        "country": "Taiwan", 
                        "zip": "80708"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung City", 
                        "country": "Taiwan", 
                        "zip": "83301"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Keelung City", 
                        "country": "Taiwan", 
                        "zip": "20401"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung City", 
                        "country": "Taiwan", 
                        "zip": "40447"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan City", 
                        "country": "Taiwan", 
                        "zip": "70457"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan City", 
                        "country": "Taiwan", 
                        "zip": "73657"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei City", 
                        "country": "Taiwan", 
                        "zip": "10449"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei City", 
                        "country": "Taiwan", 
                        "zip": "10048"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei City", 
                        "country": "Taiwan", 
                        "zip": "11217"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taoyuan County", 
                        "country": "Taiwan", 
                        "zip": "33305"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Hong Kong", 
                "Korea, Republic of", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Treatment-Naive Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects With Chronic Genotype 2 HCV Infection", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Steven Knox", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Hong Kong: Department of Health", 
                "Korea: Food and Drug Administration", 
                "Taiwan : Food and Drug Administration", 
                "Vietnam: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantification (LLOQ; ie, < 25 IU/mL) 12 weeks following the last dose of study medication.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Week 12"
            }, 
            {
                "measure": "Proportion of participants experiencing an adverse event (AE) leading to permanent discontinuation of study medication", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12, 16, or 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02021643"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of participants with: HCV RNA < LLOQ at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Weeks 4 and 24"
            }, 
            {
                "description": "Viral breakthrough was defined as HCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.", 
                "measure": "Proportion of participants experiencing viral breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12, 16, or 24"
            }, 
            {
                "description": "Viral relapse was defined as HCV RNA \u2265 LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement.", 
                "measure": "Proportion of participants experiencing viral relapse", 
                "safety_issue": "No", 
                "time_frame": "Week 12, 16, or 24 to post-treatment Week 24"
            }, 
            {
                "measure": "Change from baseline in HCV RNA (log10 IU/mL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to post-treatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}